Ozurdex (Dexamethasone)

Dexamethasone, the active ingredient in Ozurdex, is a corticosteroid presented as a sustained‑release intravitreal implant for ocular use. It is indicated for the treatment of macular edema secondary to retinal vein occlusion, diabetic macular edema, and non‑infectious uveitis in adult patients. GNH USA supplies Ozurdex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and ophthalmology clinics worldwide.

GNH USA supplies Ozurdex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and ophthalmology clinics worldwide.

Ozurdex is a corticosteroid implant used to manage inflammatory and vascular eye conditions that cause macular swelling.

- Macular edema secondary to retinal vein occlusion: reduces fluid accumulation and improves visual acuity. - Diabetic macular edema: decreases retinal swelling and stabilises vision. - Non‑infectious uveitis affecting the posterior segment: controls intra‑ocular inflammation and limits vision loss.

Ozurdex may cause ocular and systemic adverse reactions, most of which are mild to moderate.

Common Side Effects: - Elevated intra‑ocular pressure: transient rise after implantation. - Cataract formation: accelerated lens opacity with repeated exposure. - Conjunctival hyperemia: redness around the injection site. - Floaters: visual disturbances from implant particles. - Vitreous hemorrhage: minor bleeding during or after procedure.

Serious or Rare Side Effects: - Endophthalmitis: intra‑ocular infection requiring urgent treatment. - Retinal detachment: separation of retinal layers. - Persistent elevated intra‑ocular pressure requiring surgery. - Severe cataract necessitating extraction. - Implant migration to the anterior chamber. - Vision loss not attributable to underlying disease.

Before using Ozurdex, clinicians should assess ocular health and systemic risk factors.

- Monitor intra‑ocular pressure: check regularly after implantation. - Evaluate for glaucoma history: patients with uncontrolled glaucoma may be unsuitable. - Assess lens status: pre‑existing cataract may progress faster. - Avoid in active ocular infection: implantation can worsen infection. - Use caution in patients on systemic steroids: additive pressure‑raising effect possible. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ozurdex may interact with other ocular or systemic therapies that influence intra‑ocular pressure or inflammation.

Major Interactions (Avoid): - Concurrent intravitreal anti‑VEGF agents: may increase risk of ocular hypertension. - Systemic corticosteroids: additive effect on intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Topical ocular steroids: monitor pressure if used together. - Antiglaucoma medications: dose adjustments may be needed. - Anticoagulants: may increase risk of vitreous hemorrhage during implantation. - NSAIDs: may affect wound healing post‑procedure. - Immunosuppressants: heightened infection risk, monitor closely.